SDK1: A Protein Potential Drug Target Or Biomarker (G221935)

Target Name: SDK1

NCBI ID: G221935

SDK1

SDK1: A Protein Potential Drug Target Or Biomarker

SDK1 (Protein sidekick-1 (isoform 1)) is a protein that is expressed in various tissues throughout the body. It is a member of the Sucrase synthase family and is involved in the catalytic cycle of DNA replication. SDK1 has also been shown to play a role in the regulation of gene expression and has been linked to a number of diseases, including cancer. As a result, SDK1 has generated a lot of interest as a potential drug target or biomarker.

The protein sidekick-1 gene was identified in the late 1990s and has since been shown to encode a protein that is highly conserved across various species. SDK1 is composed of 254 amino acid residues and has a calculated molecular weight of 31 kDa. The protein is expressed in a variety of tissues, including muscle, liver, and brain, and is thought to play a role in the regulation of cellular processes such as DNA replication, transcription, and translation.

One of the unique features of SDK1 is its ability to interact with DNA. It has been shown that SDK1 can form a complex with the protein responsible for the polar DNA-binding protein, NIP (Nucleotide-binding protein). This complex is thought to play a role in the regulation of gene expression and is involved in the process of DNA replication.

In addition to its role in DNA replication, SDK1 has also been shown to play a role in the regulation of gene expression. It has been shown to interact with a number of transcription factors, including T-cell factor (TGF-β), and to regulate the activity of these factors. This suggests that SDK1 may be involved in the regulation of cellular processes such as cell growth, differentiation, and apoptosis.

The link between SDK1 and cancer is an area of 鈥嬧?媜ngoing research. It is thought that the levels of SDK1 are elevated in a number of cancer types, including breast, ovarian, and prostate cancer. This suggests that SDK1 may be a potential drug target or biomarker for these diseases.

In addition to its potential as a drug target or biomarker, SDK1 has also been shown to have a number of potential therapeutic applications. For example, it has been shown to be involved in the regulation of the immune response and to play a role in the development of cancer. It is also thought to be involved in the regulation of inflammation, which is a major risk factor for a number of diseases, including cancer.

In conclusion, SDK1 is a protein that has been shown to play a number of roles in various cellular processes throughout the body. Its unique ability to interact with DNA and its involvement in the regulation of gene expression make it a promising candidate as a drug target or biomarker. Further research is needed to fully understand the role of SDK1 in cellular processes and its potential therapeutic applications.

Protein Name: Sidekick Cell Adhesion Molecule 1

Functions: Adhesion molecule that promotes lamina-specific synaptic connections in the retina. Expressed in specific subsets of interneurons and retinal ganglion cells (RGCs) and promotes synaptic connectivity via homophilic interactions

The "SDK1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SDK1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets